Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Pulmonary/Respiratory Diseases | Musculoskeletal | Infections and Infectious Diseases
Inflammation Clinical Trials
A listing of Inflammation medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Huntsville : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Tuscaloosa : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Arizona
Mesa : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Phoenix : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Scottsdale : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
California
Glendale : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Hemet : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Hemet : Inland Eye Specialists
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Huntington Beach : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Huntington Beach : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
View More »
La Jolla : Novo Nordisk Clinical Trial Call Center
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
La Mesa : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
La Mesa : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
La Mesa : Sharp Grossmont Hospital
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Lakewood : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Long Beach : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Los Angeles : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Los Angeles : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Los Angeles : UCLA CARE Center CRS (601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Placentia : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Placentia : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Sacramento : Dialysis Clinics Inc
Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis
San Diego : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
San Diego : Ucsd, Avrc Crs (701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
San Diego : Rady Children's Hospital Dermatolgoy
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
San Francisco : University of California, San Francisco
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
Santa Monica : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Simi Valley : Simi Valley Dialysis Center
An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients
Temecula : California Eye Professionals
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Torrance : Harbor-UCLA Med. Ctr. CRS (603)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Upland : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Upland : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Colorado
Aurora : University of Colorado Hospital CRS (6101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Denver : Denver Public Health CRS
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Denver : National Jewish Health
Markers of Airway Inflammation in BAL Fluid From Children With Asthma
Connecticut
New Haven : Yale new Haven Hospital
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
District of Columbia
Washington : Georgetown University CRS (GU CRS) (1008)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Florida
Boca Raton : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Coral Springs : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Fort Lauderdale : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Gainesville : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Jupiter : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
View More »
Miami : Division of Pulmonary and Critical Care, Human Reseach, U of Miami Updated
Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
New Port Richey : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Ocala : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Orlando : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Palm Harbor : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Tampa Bay : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Venice : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
West Palm Beach : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Georgia
Decatur : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Idaho
Idaho Falls : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Illinois
Chicago : Northwestern University CRS (2701)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Hoffman Estates : Chicago Cornea Consultants, Ltd. Updated
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Springfield : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Springfield : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Indiana
Indianapolis : Indiana Clinical and Translational Sciences Institute
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
Rock Island : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Rock Island : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
South Bend : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
South Bend : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Kansas
Kansas City : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Wichita : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Wichita : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Kentucky
Edgewood : Cincinnati Eye Institute
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Elizabethtown : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Elizabethtown : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Lexington : University of Kentucky Medical Cener
Effects of Fish Oils on Inflammation and Insulin Resistance
Louisiana
Lake Charles : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Lake Charles : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Shreveport : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Maryland
Baltimore : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Cumberland : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Hagerstown : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Massachusetts
Boston : Brigham and Women's Hosp. ACTG CRS (107)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Massachusetts General Hospital ACTG CRS (101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Boston : Massachusetts General Hospital
Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients
Boston : Ophthalmic Partners of Boston
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
View More »
North Andover : ORA Study Sites
Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery
Worcester : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Michigan
Ann Arbor : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Battle Creek : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Detroit : Henry Ford Hosp. CRS (31472)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Detroit : Wayne State Univ. CRS
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Kalamazoo : Western Michigan University
The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
Minnesota
Stillwater : Associated Eye Care
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Mississippi
Flowood : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Missouri
Hazelwood : Healthcare Research Network
Do you have Gout? Are you 18+ years old? If so, you may qualify for our study! Call us today to find out more information.
Hazelwood : Healthcare Research Network
Do you have Osteoarthritis of the Knee? Are you between 40-80 years old? If so, you may qualify for our study! Call us today to find out more information.
View More »
Saint Louis : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
St. Louis : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
St. Louis : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
St. Louis : Washington U CRS (2101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
St. Louis : Washington University School of Medicine
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (10-0188, Pfizer)
Montana
Kalispell : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Nebraska
Lincoln : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
New Jersey
Camden : Cooper Univ. Hosp. CRS (31476)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Clifton : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Freehold : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Freehold : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Newark : New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Toms River : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Toms River : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
New Mexico
Albuquerque : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Albuquerque : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
New York
Bronx : Biomedical Research Alliance of New York
Japanese Encephalitis (inflammation of the brain) - Pediatric Population
View More »
Albany : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Brooklyn : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Brooklyn : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Great Neck : North Shore-Long Island Jewish Health System, Division of Allergy/Immunology
The Effect of Montelukast on Asthma Control in Obese Asthmatic Children and Adolescents
New York : NY Univ. HIV/AIDS CRS (401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New York : Cornell CRS (7804)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
New york : New York presbyterian Weill Cornell Medical center
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Rochester : Univ. of Rochester ACTG CRS (1101)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Rochester : Bausch & Lomb Incorporated
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Rochester : Bausch & Lomb, Incorporated
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Roslyn : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Roslyn : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
North Carolina
Chapel Hill : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Chapel Hill : Unc Aids Crs (3201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Charlotte : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Charlotte : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Durham : Duke Univ. Med. Ctr. Adult CRS (1601)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Greensboro : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Greenville : Brody School of Medicine
Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Heart Function in Patients With Mitral Valve Disease
Raleigh : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Wilmington : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Ohio
Beachwood :
Mucin Balls and Corneal Inflammation Events
Cincinnati : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Cincinnati : Univ. of Cincinnati CRS (2401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cleveland : Case CRS (2501)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Cleveland : Metro Health CRS (2503)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
View More »
Cleveland :
Mucin Balls and Corneal Inflammation Events
Columbus : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Columbus :
Mucin Balls and Corneal Inflammation Events
Toledo : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Oklahoma
Norman : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Norman : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Oklahoma City : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Oregon
Bend : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Lake Oswego : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Pennsylvania
Hershey : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Philadelphia : Hosp. of the Univ. of Pennsylvania CRS (6201)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Pittsburgh : Pitt CRS (1001)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Pittsburgh : University of Pittsburgh Medical Center
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
South Carolina
Charleston : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Columbia : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Orangeburg : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Tennessee
Jackson : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Jackson : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Memphis : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Memphis : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Texas
Amarillo : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Austin : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Houston : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Houston : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Houston : Novo Nordisk Clinical Trial Call Center
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
View More »
Houston : Houston AIDS Research Team CRS (31473)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
McKinney : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Mesquite : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Mesquite : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Sugar Land : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Waco : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Virginia
Arlington : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Richmond : Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Washington
Seattle : University of Washington AIDS CRS (1401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Seattle : Virginia Mason Medical Center
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Tacoma : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
West Virginia
Beckley : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Beckley : Novo Nordisk Clinical Trial Call Center
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Argentina
Buenos Aires :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Buenos Aires :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Belgium
Liege :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Liege :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Brazil
Sao Paulo :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Vila Clementino :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Bulgaria
Sofia :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Stara Zagora :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Canada
Calgary : University of Calgary, Foothills Hospital
Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins
Montreal : Innovaderm Research Inc
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
St-Hyacinthe : Clinique Médicale Dr Isabelle Delorme
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Croatia
Zagreb :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Czech Republic
Olomouc :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
Praha 11 :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Denmark
Aarhus : Department of Endocrinology, Aarhus University Hospital
"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"
Aarhus :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Aarhus : Department of Rheumatology U, Aarhus Hospital
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Aarhus, C : Department of Endocrinology, Aarhus University Hospital
"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"
Copenhagen : Centre of Inflammation and Metabolism - Rigshospitalet 7641
Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
View More »
Horsens : Regional Hospital of Horsens, Department of Medicine
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Randers : Regional Hospital of Randers, Department of Medicine
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Silkeborg : Regional Hospital of Silkeborg
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
France
Bordeaux :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Cornebarrieu :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Creteil :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
La Tronche :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Limoges :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
View More »
Lyon :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Lyon Cedex 3 :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Marseille :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Marseille : Institut Paoli Calmettes
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Nice :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Paris :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Toulouse :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Germany
Berlin : Updated
First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
Berlin :
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis
Berlin :
Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
Frankfurt :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Halle (Saale) : Martin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, Klinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Ernst-Grube-Strasse 40
The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing
View More »
Hamburg :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Hannover : Fraunhofer Institut fur Toxicologie und Experimentelle Medicine (ITEM)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
Hungary
Budapest :
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
Gyula :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Veszprem :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Veszprém :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Italy
Bari :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Bologna : Dept Internal Medicine and Gastroenterology, Policlinico Sant'Orsola-Malpighi
Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients
Catanzaro :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Genova :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Jesi :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
View More »
Milano :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Perugia :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Pisa :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Roma : Policlinico Univertitario Agostino Gemelli
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Rome :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Trieste :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Korea, Republic of
Seoul : Bausch & Lomb Korea Ltd
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
Latvia
Riga :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Mexico
Chihuahua :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Mexico City :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Netherlands
Eindhoven : Catharina Ziekenhuis, Dept. CardioThoracic Surgery
Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery
Utrecht : University Medical Center Utrecht
Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
Poland
Bialystok :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Katowice :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Katowice :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Krakow :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Poznan :
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
Portugal
Lisboa :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Porto :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Puerto Rico
San Juan : Puerto Rico-AIDS CRS (5401)
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Russian Federation
Moscow :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
Moscow :
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis
Skt. Petersburg :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Serbia
Belgrade :
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
Niska Banja :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Spain
A.Coruna :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Barcelona :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Barcelona :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Bilbao :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Granada :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
View More »
La Coruña :
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
Madrid :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
Madrid :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Majadahonda :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Sevilla :
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
Ukraine
Odessa :
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
United Kingdom
Cambridge : Cambridge University Hospitals NHS Foundation Trust
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
Epsom : South West London Elective Orthopaedic Center
Bipolar Sealer Aquamantys Use in Total Knee Replacement
London :
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
London : Royal Brompton & Harefield NHS Foundation Trust
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
